References
- Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol.180, 180–202 (2002).
- Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nat. Med.2, 561–566 (1996).
- Kantarjian HM, Smith TL, O’Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service. Ann. Intern. Med.122, 254–261 (1995).
- Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood94, 1517–1536 (1999).
- Schindler T, Bornmann W, Pellicena P et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science289, 1938–1942 (2000).
- Druker B, Guilhot F, O’Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355(23), 2408–2417 (2006).
- Cortes J, Giles F, Salvado AJ et al. Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group. Blood108, 609A (2006).
- Mauro MJ. Defining and managing imatinib resistance. Hematology Am. Soc. Hematol. Educ. Program219–225 (2006).
- Shah NP. Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Cancer Chemother. Pharmacol.58, 49–53 (2006).
- Wei Y, Hardling M, Olsson B et al. Not all imatinib resistance in CML are BCR–ABL kinase domain mutations. Ann. Hematol.85, 841–847 (2006).
- Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood108, 1809–1820 (2006).
- Branford S, Cross NC, Hochhaus A et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR–ABL transcripts in patients with chronic myeloid leukaemia. Leukemia20, 1925–1930 (2006).
- Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle5(24) 2862–2866 (2006).
- Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med.12, 1181–1184 (2006).
- Ohno R. Treatment of chronic myeloid leukemia with imatinib mesylate. Int. J. Clin. Oncol.11, 176–183 (2006).
- Giles FJ, Cortes JE, Jones D, Bergstrom DA, Kantarjian HM, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR–ABL mutation. Blood109(2), 500–502 (2006).